Description
Recombinant human erythropoietin (EPO) is a glycoprotein hormone with a molecular weight of 34 kDa, consisting of 165 amino acids. It is the primary regulatory factor in mammals for the control of erythropoiesis (red blood cell production). Studies have shown that in vivo transfection of EPO mRNA leads to a significant increase in reticulocytes and hematocrit levels, and it is commonly used in immunological and biochemical research.
This product is synthesized using the T7 High Yield RNA Transcription kit (Novoprotein, Cat.No.: E131) and modified with the Cap 1 Capping System (Novoprotein, Cat.No.: M082) to achieve a mature mRNA structure with a 5' Cap 1 structure and a 3' poly(A) tail. By introducing N1-Me-Pseudo UTP to replace natural UTP, the immunogenicity of the mRNA in mammalian cells is effectively reduced, while enhancing its stability.
